A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali

dc.contributor.authorAwandare, G.A.
dc.contributor.authorDiakité, S.A.S.
dc.contributor.authorTraoré, K.
dc.contributor.authorSanogo, I.
dc.contributor.authorClark, T.G.
dc.contributor.authorCampino, S.
dc.contributor.authorSangaré, M.
dc.contributor.authorDabitao, D.
dc.contributor.authorDara, A.
dc.contributor.authorKonaté, D.S.
dc.contributor.authorDoucouré, F.
dc.contributor.authorCissé, A.
dc.contributor.authorKeita, B.
dc.contributor.authorDoumbouya, M.
dc.contributor.authorGuindo, M.A.
dc.contributor.authorToure, M.B.
dc.contributor.authorSogoba, N.
dc.contributor.authorDoumbia, S.
dc.contributor.authorDiakité, M.
dc.date.accessioned2019-11-22T16:41:47Z
dc.date.available2019-11-22T16:41:47Z
dc.date.issued2019-11-12
dc.descriptionResearch Articleen_US
dc.description.abstractBackground: Drug resistance is one of the greatest challenges of malaria control programme in Mali. Recent advances in next-generation sequencing (NGS) technologies provide new and effective ways of tracking drug-resistant malaria parasites in Africa. The diversity and the prevalence of Plasmodium falciparum drug-resistance molecular markers were assessed in Dangassa and Nioro-du-Sahel in Mali, two sites with distinct malaria transmission patterns. Dangassa has an intense seasonal malaria transmission, whereas Nioro-du-Sahel has an unstable and short seasonal malaria transmission. Methods: Up to 270 dried blood spot samples (214 in Dangassa and 56 in Nioro-du-Sahel) were collected from P. falciparum positive patients in 2016. Samples were analysed on the Agena MassARRAY ® iPLEX platform. Specific codons were targeted in Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps, Pfarps10, Pfferredoxin, Pfexonuclease and Pfmdr2 genes. The Sanger’s 101-SNPs-barcode method was used to assess the genetic diversity of P. falciparum and to determine the parasite species. Results: The Pfcrt_76T chloroquine-resistance genotype was found at a rate of 64.4% in Dangassa and 45.2% in Nioro-du-Sahel (p = 0.025). The Pfdhfr_51I-59R-108N pyrimethamine-resistance genotype was 14.1% and 19.6%, respectively in Dangassa and Nioro-du-Sahel. Mutations in the Pfdhps_S436-A437-K540-A581-613A sulfadoxine-resistance gene was significantly more prevalent in Dangassa as compared to Nioro-du-Sahel (p = 0.035). Up to 17.8% of the isolates from Dangassa vs 7% from Nioro-du-Sahel harboured at least two codon substitutions in this haplotype. The amodiaquine-resistance Pfmdr1_N86Y mutation was identified in only three samples (two in Dangassa and one in Nioro-du-Sahel). The lumefantrine-reduced susceptibility Pfmdr1_Y184F mutation was found in 39.9% and 48.2% of samples in Dangassa and Nioro-du-Sahel, respectively. One piperaquine-resistance Exo_E415G mutation was found in Dangassa, while no artemisinin resistance genetic-background were identified. A high P. falciparum diversity was observed, but no clear genetic aggregation was found at either study sites. Higher multiplicity of infection was observed in Dangassa with both COIL (p = 0.04) and Real McCOIL (p = 0.02) methods relative to Nioro-du-Sahel. Conclusions: This study reveals high prevalence of chloroquine and pyrimethamine-resistance markers as well as high codon substitution rate in the sulfadoxine-resistance gene. High genetic diversity of P. falciparum was observed. These observations suggest that the use of artemisinins is relevant in both Dangassa and Nioro-du-Sahel.en_US
dc.description.sponsorshipDiakite SAS is supported by a DELTAS Africa grant (DEL-15-007: Awandare). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (107755/Z/15/Z: Awandare) and West Africa ICEMR (2). Genotyping was done at the Sanger Institute thanks to the Wellcome Trust Sanger Institute Grant No. 098051 to DK. TGC is funded by the Medical Research Council UK (Grant No. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and MR/R020973/1) and BBSRC (Grant No. BB/R013063/1). SC is funded by Medical Research Council UK Grants (MR/M01360X/1, MR/R025576/1, and MR/ R020973/1) and BBSRC (Grant No. BB/R013063/1).en_US
dc.identifier.otherhttps://doi.org/10.1186/s12936-019-2986-5
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/33798
dc.language.isoenen_US
dc.publisherMalaria Journalen_US
dc.relation.ispartofseries18;361
dc.subjectPlasmodium falciparumen_US
dc.subjectDrug-resistanceen_US
dc.subjectMolecular surveillanceen_US
dc.subjectNext-generation sequencingen_US
dc.titleA comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Malien_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
A-comprehensive-analysis-of-drug-resistance-molecular-markers-and-Plasmodium-falciparum-genetic-diversity-in-two-malaria-endemic-sites-in-MaliMalaria-journal.pdf
Size:
959.01 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: